NASDAQ : IDYA
IDEAYA Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 32.89 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.17B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.08B |
| Enterprise Value | 1.87B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 96.49M |
| Shares Outstanding | 96.49M |
| Shares Change (YoY) | +2.12% |
| Shares Change (QoQ) | +3.79% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 102.49% |
| Float | 90.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.17 |
| Forward PS | 55.39 |
| PB Ratio | 2.57 |
| P/TBV Ratio | 2.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 7.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.45 |
| Quick Ratio | 10.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -16.22% |
| Return on Assets (ROA) | -11.54% |
| Return on Invested Capital (ROIC) | -12.25% |
| Return on Capital Employed (ROCE) | -17.68% |
| Weighted Average Cost of Capital (WACC) | 4.00% |
| Revenue Per Employee | $1.61M |
| Profits Per Employee | -$1.21M |
| Employee Count | 145 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.04 |
| 52-Week Price Change | -0.68% |
| 50-Day Moving Average | 37.24 |
| 200-Day Moving Average | 34.02 |
| Relative Strength Index (RSI) | 34.56 |
| Average Volume (20 Days) | 877,120 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.08M |
| Short Previous Month | 9.18M |
| Short % of Shares Out | 9.41% |
| Short % of Float | 10.02% |
| Short Ratio (days to cover) | 9.87 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 234.13M |
| Gross Profit | -139.88M |
| Operating Income | -216.95M |
| Pretax Income | -175.02M |
| Net Income | -175.02M |
| EBITDA | -214.20M |
| EBIT | -216.95M |
| Loss Per Share | -$1.96 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 828.96M |
| Total Debt | 29.31M |
| Net Cash | 1.21B |
| Net Cash Per Share | $12.58 |
| Equity (Book Value) | 1.20B |
| Book Value Per Share | 12.44 |
| Working Capital | 781.35M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -111.66M |
| Capital Expenditures | -2.21M |
| Depreciation & Amortization | 2.76M |
| Net Borrowing | n/a |
| Free Cash Flow | -113.87M |
| FCF Per Share | -$1.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | -59.75% |
| Operating Margin | -92.66% |
| Pretax Margin | -74.75% |
| Profit Margin | -74.75% |
| EBITDA Margin | -91.49% |
| EBIT Margin | -92.66% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.12% |
| Shareholder Yield | -2.12% |
| Earnings Yield | -6.12% |
| FCF Yield | -3.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $51.92 |
| Price Target Difference | 62.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 6.26% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 13.67 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |